Condition: Craniopharyngioma · Sponsor: Eva Marie Erfurth, MD, PhD
Subjects with papillary craniopharyngioma harboring a BRAF mutation will be treated with a BRAF + MEK inhibitor (dabrafenib + trametinib) after informed consent. Study participants will be administered oral dabrafenib and trametinib until maximal tumor volume reduction assessed by MRI. Progression free survival, cognition, ophthalmologic status, hypothalamic status and quality of life will be assessed 1 year after initiation of study treatment
This description comes directly from the study's public registry record.
Eva Marie Erfurth, MD. PhD. · +4646172363 · eva_marie.erfurth@med.lu.se
Sara Kinhult, MD. PhD. · +4646177587 · sara.kinhult@skane.se
Always discuss trial participation with your own doctor first.
| Department of Endocrinology | Lund, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05525273